ContraFect to Present at FDA Workshop on Advancing Animal Models for Antibacterial Drug Development March 4, 2020
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis February 24, 2020
ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology February 3, 2020
ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) January 27, 2020
ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections January 13, 2020
ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis January 10, 2020
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis December 20, 2019
